<DOC>
	<DOCNO>NCT01818232</DOCNO>
	<brief_summary>This phase 1 study evaluate pharmacokinetics ( PK ) , metabolism , rout extent elimination single oral dose 400 mg [ 14C ] LX4211 healthy male subject</brief_summary>
	<brief_title>Study Determine Absorption , Metabolism , Excretion 14CLX4211 Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Adults ≥18 ≤55 year age Vital sign Screening follow range : systolic blood pressure , 90140 mm Hg ; diastolic blood pressure , 5090 mm Hg ; heart rate , 50100 bpm Body mass index ( BMI ) ≥18 ≤35 kg/sq Historically able produce minimum 1 bowel movement per day Willing able provide write informed consent Female Receipt investigational drug within 30 day prior Dosing , investigational protein antibodybased therapeutic agent within 3 month prior Screening Prior exposure LX4211 Use tobacco product within 2 month prior Screening participate study ( Day 1 Discharge ) History bariatric surgery GI surgery may induce malabsorption History major surgery within 6 month prior Screening History renal hepatic disease , significantly abnormal kidney liver function test Screening History clinically relevant psychiatric , renal , hepatic , pancreatic , cardiovascular , neurological , hematological , GI abnormality History active infection within 14 day prior Dosing History alcohol substance abuse within 2 year prior Dosing History human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C Donation loss &gt; 400 mL blood blood product within 3 month Dosing Positive urine glucose Screening Positive urine screen drug abuse Screening Day 1 Positive breath test alcohol Screening Day 1 Participation &gt; 1 radiolabeled investigational study drug trial within 12 month prior Day 1 Exposure significant radiation within 12 month prior Day 1</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>